Answers are grounded in this paper and cite their sources.
Prospective cohort study explores HDMTX-related toxicities in children with ALL, suggesting improved monitoring strategies.
High-dose methotrexate (HDMTX) constitutes a critical component of modern pediatric acute lymphoblastic leukemia (ALL) protocols, significantly improving disease control and survival. However, treatment-related toxicities frequently interrupt therapy and influence outcomes, particularly in resource-constrained environments. This article studies the incidence, spectrum, and predictors of HDMTX-related toxicities in children with ALL. A prospective cohort study was conducted over 18 months, including 40 children aged 1 to 12 years receiving HDMTX therapy, contributing a total of 138 HDMTX cycles for analysis. Toxicities were graded using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Serial hematological, hepatic, and renal parameters were assessed at baseline, 24 hours, 48 hours, and day 7 postinfusion. Risk factors were evaluated using multivariate logistic regression, with analyses performed at the cycle level to account for repeated observations per patient. Across 138 HDMTX cycles derived from 40 patients, anemia was the most common hematological toxicity (94.9%), followed by thrombocytopenia (31.9%) and febrile neutropenia (23.2%). Hepatotoxicity occurred in 89.1% of cycles, but renal toxicity was infrequent (1.4%). The T-cell immunophenotype independently predicted febrile neutropenia (adjusted odds ratio [OR] 2.84, 95% confidence interval [CI] 1.19–6.77; p = 0.018) and mucositis (adjusted OR 3.21, 95% CI 1.39–7.41; p = 0.006). Female gender was associated with elevated transaminases (adjusted OR 2.57, 95% CI 1.25–5.29; p = 0.011), while the first HDMTX cycle predicted thrombocytopenia (adjusted OR 2.33, 95% CI 1.09–4.98; p = 0.028). Hematological parameters showed transient nadirs at 48 hours with recovery by day 7. HDMTX demonstrates acceptable safety when delivered with standardized supportive care. Early identification of clinical risk factors enables individualized toxicity monitoring and optimization of treatment delivery in pediatric ALL.
No takes yet. Share an insight, caveat, or question.
Jha et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: